WallStreetZenWallStreetZen

NASDAQ: NAUT
Nautilus Biotechnology Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their NAUT stock forecasts and price targets.

Forecast return on equity

Is NAUT forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.66%

Forecast return on assets

Is NAUT forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

NAUT revenue forecast

What is NAUT's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$3.8M
Avg 2 year Forecast
$9.7M
Avg 3 year Forecast
$27.2M

NAUT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NAUT$2.34N/AN/A
VRCA$6.90$10.33+49.75%Strong Buy
AKBA$1.39$5.00+259.71%Strong Buy
MGX$7.75$21.40+176.13%Strong Buy
TERN$4.59$13.50+194.12%Buy

Nautilus Biotechnology Stock Forecast FAQ

What is NAUT's revenue growth forecast for 2024-2026?

(NASDAQ: NAUT) Nautilus Biotechnology's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.23%.

Nautilus Biotechnology's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast NAUT's revenue for 2024 to be $472,745,644, with the lowest NAUT revenue forecast at $472,745,644, and the highest NAUT revenue forecast at $472,745,644. On average, 2 Wall Street analysts forecast NAUT's revenue for 2025 to be $1,212,075,297, with the lowest NAUT revenue forecast at $472,745,644, and the highest NAUT revenue forecast at $1,951,530,048.

In 2026, NAUT is forecast to generate $3,408,797,582 in revenue, with the lowest revenue forecast at $3,408,797,582 and the highest revenue forecast at $3,408,797,582.

If you're new to stock investing, here's how to buy Nautilus Biotechnology stock.

What is NAUT's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: NAUT) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is NAUT's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: NAUT) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.